SCHEMBL6487093

SCHEMBL6487093

Cc1cc(Cc2ccc(C(=O)O)cc2)c(=O)n2cc(C(=O)NCc3ccccc3)oc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 4/20 0.46
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C19 P33261 1/20 0.43
EPHX2 P34913 2/20 0.42
GNRHR P30968 1/20 0.42
ATM Q13315 1/20 0.41
TP53 P04637 1/20 0.41
EGFR P00533 1/20 0.41
SRC P12931 1/20 0.41
PHGDH O43175 1/20 0.41
KLKB1 P03952 1/20 0.40
KLK1 P06870 1/20 0.40
MMP13 P45452 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476432 0.90 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL6818481 0.90 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL6483747 0.81 NR1H4 (0.44) NR1H4ALDH1A1HPGDKDM4EMEN1
SCHEMBL6488185 0.80 TRPA1 (0.53) NR1H4ALDH1A1HPGDEPHX2PHGDH
SCHEMBL6483805 0.80 KLK1 (0.47) NR1H4ALDH1A1HPGDKDM4EEPHX2
SCHEMBL6292189 0.77 POLB (0.46) NR1H4ALDH1A1HPGDEPHX2TP53
SCHEMBL6486746 0.74 NR1H4 (0.45) NR1H4ALDH1A1HPGDKDM4EEPHX2
SCHEMBL6292153 0.74 EGFR (0.45) NR1H4ALDH1A1MEN1KMT2AEPHX2
SCHEMBL6819023 0.73 MMP13 (0.38) NR1H4ALDH1A1HPGDKDM4EMEN1
SCHEMBL6488181 0.73 NR1H4 (0.44) NR1H4ALDH1A1HPGDKDM4EEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 NR1H4 2002/4885ALDH1A1 251/4885HPGD 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.